cms.bioaccessla.com

Tag: ANVISA

  • ICH E6(R3) Annex 2 Just Hit Step 4 In Rio. Argentina Is Positioned To Be Latin America’s First Adopter. Here’s What That Means For Medtech Sponsors.

    On June 3, 2026, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use convened its biannual Assembly in Rio de Janeiro — the first ICH meeting ever held in Latin America. Brazil’s health regulator, ANVISA, hosted. Among the multiple guidelines under consideration at the meeting, only one was advanced to Step 4 — the final stage of ICH adoption: E6(R3) Annex 2, the guideline that codifies decentralized clinical trial design, pragmatic study architectures, digital health technologies, and real-world data as integral elements of GCP-compliant clinical research.

    For a Latin American clinical research operator that has spent the past sixteen years arguing the case to MedTech, biotech, and radiopharma founders, the June 1 to June 4 sequence in Rio is the most strategically significant positioning event of 2026. The geographic precedent is itself meaningful — ICH governance has historically convened in Geneva, Brussels, Tokyo, or other established regulatory capitals. Selecting Rio de Janeiro and partnering with ANVISA as host signals a structural shift in how ICH governance views Latin American regulatory infrastructure. The substantive outcome — only one guideline elevated to Step 4 at the meeting, and that guideline being the one that defines modern trial design — matters even more for how sponsors will think about LATAM site sequencing over the next 18 to 24 months.

    This post unpacks what Annex 2 actually changes, why the Rio venue matters, and how MedTech sponsors should think about Argentina’s position as the first Latin American jurisdiction structurally ready to accept Annex 2-compliant protocols without amendment.

    What ICH E6(R3) Annex 2 Actually Changes

    ICH E6(R3) is the current Good Clinical Practice (GCP) guideline that all major regulators — FDA, EMA, MHRA, PMDA, Health Canada, and adopting regulators in Latin America — converge on for clinical trial conduct. The most recent revision moved GCP to a risk-based, principle-driven model. Annex 2 extends E6(R3) to explicitly cover the trial designs that have become operational reality over the past five years but lacked formal codification in GCP guidance.

    Specifically, Annex 2 addresses:

    • Decentralized clinical trials (DCTs) — trials where participant interaction with study sites is partially or fully replaced by remote visits, home-based assessments, mobile health units, or telehealth consultations.
    • Pragmatic trial designs — protocols built around real-world clinical settings, with broader patient populations and less restrictive inclusion criteria than traditional efficacy trials.
    • Remote site visits — sponsor monitoring conducted through electronic data review, remote source verification, and risk-based on-site oversight rather than universal in-person visits.
    • Digital health technology (DHT) data capture — continuous glucose monitors, wearable cardiac telemetry, accelerometer-based motion data, smartphone-based patient-reported outcomes, and similar tools used as primary or secondary endpoint capture methods.
    • Real-world data (RWD) — use of electronic health records, claims data, registries, and other non-trial sources as supporting evidence within GCP-compliant studies.
    • Adaptive designs — pre-specified protocol modifications based on accumulating trial data, including sample size re-estimation and arm-dropping decisions.

    The substantive shift in Annex 2 is not new regulation. It is the formal incorporation of these design elements into GCP rather than treating them as exceptions that require special justification. For sponsors who have been building modern trial designs over the past five years, the legal architecture finally caught up with the operational reality.

    Why The Rio Venue Matters

    ICH Assembly meetings rotate among the home jurisdictions of ICH members. Hosting the meeting is a substantive role — the host regulator coordinates logistics, sets the agenda for site-specific discussions, and shapes the framing of how the meeting’s outcomes are communicated to global stakeholders. ANVISA hosting the June 2026 Assembly is the strongest signal to date that Brazilian regulatory infrastructure is converging with ICH governance not as an observer but as an active participant.

    For Brazilian sponsors and CROs, the immediate implication is that ANVISA’s preparation for formal E6(R3) adoption is now visible in a way it was not six months ago. The May 28, 2026 ANVISA board session that explicitly addressed ICH E6 and E8 implementation preparation was the first concrete signal. The June 3 Assembly hosting is the next, much stronger signal. Brazilian formal E6(R3) adoption has no publicly announced timeline yet, but the operational trajectory is no longer in doubt.

    For Argentina, the implication is different but equally substantive. Argentina’s ANMAT, under Disposición 7516/25 operative since December 1, 2025, already maintains a regulatory framework aligned with E6(R3) principles. Argentina did not need to host the Rio Assembly to be ready for Annex 2 — it was already there. What the Rio Assembly does for Argentina is confirm that its regulatory positioning was correctly anticipated, and accelerate the speed at which ANMAT can absorb Annex 2-aligned protocols from sponsors.

    Argentina As The First LATAM Annex 2-Ready Jurisdiction

    Disposición 7516/25 modernized Argentina’s clinical trial framework along several dimensions that align directly with E6(R3) principles: a 62-day parallel ethics and agency review pathway, ICH E6(R3) substantive alignment in protocol structure expectations, and operational mechanisms for risk-based monitoring and remote oversight. Critically for Annex 2, Disposición 7516/25 does not preclude decentralized design elements, DHT data capture, or pragmatic patient populations — it accommodates them.

    The practical consequence is that sponsors designing Annex 2-compliant protocols for FDA or EMA submission in 2026 and 2027 do not face a structural barrier to LATAM site inclusion when Argentina is the lead LATAM jurisdiction. Brazil, Colombia, Mexico, and other LATAM regulators have not formally adopted E6(R3), let alone Annex 2 — meaning protocols built around decentralized or DHT-enabled designs face higher regulatory friction in those jurisdictions until each regulator adopts the guidance domestically.

    For Brazil, the trajectory is unambiguous post-Rio. ANVISA hosting the Assembly, the May 28 board session on E6 and E8 preparation, and the substantive operational alignment between ANVISA’s technovigilance and clinical research frameworks all point toward formal E6(R3) adoption in 2026 or 2027. Annex 2 acceptance follows.

    For Mexico (COFEPRIS), Colombia (INVIMA), and other LATAM regulators, the path is less defined. Colombia’s pending Decreto Único de Dispositivos Médicos e In Vitro (currently in WTO comment phase with a July 17 deadline) introduces international reliance pathways that may indirectly accelerate Annex 2 acceptance, but no formal adoption has been signaled.

    Operational Implications For MedTech Sponsors Designing 2026-2027 Protocols

    For a MedTech sponsor designing a protocol today for a 12 to 18 month FIH-to-pivotal sequence, three operational questions matter immediately.

    First, should the protocol be built Annex 2-compliant from the start? The answer is almost always yes if any of the following apply: DHT-collected endpoints are part of the endpoint set; the patient population is large enough that pragmatic design considerations would materially expand enrollment; remote visits or telehealth consultations would meaningfully reduce participant burden; or the trial design contemplates pre-specified adaptive elements such as sample size re-estimation. Building Annex 2-compliant from the start adds modest protocol-authoring effort and substantial future flexibility.

    Second, how should LATAM country sequencing change? For 2026 and through Q2 2027, Argentina-primary is now the recommended LATAM lead jurisdiction for any Annex 2-aligned design. Disposición 7516/25 is the only operative LATAM framework that can absorb the design without amendment. Brazil-secondary is appropriate as ANVISA formalizes its adoption. Mexico and Colombia remain opportunistic, evaluated on therapeutic-area depth and sponsor-specific operational requirements rather than as primary LATAM hubs for decentralized designs.

    Third, what about sponsors with existing LATAM site relationships built around traditional trial architectures? The Annex 2 guidance does not invalidate traditional trial designs. Sponsors running fully on-site, non-decentralized protocols can continue without adjustment. The shift matters for sponsors whose product strategy is built around DHT-collected endpoints or decentralized data capture — for whom the regulatory architecture in LATAM was previously a bottleneck and now is not.

    What Comes Next

    National regulator implementation of E6(R3) Annex 2 will proceed on independent timelines through 2026 and 2027. FDA has signaled implementation guidance is forthcoming. EMA has indicated alignment without formal adoption schedule. PMDA and Health Canada are expected to follow. In Latin America, ANMAT is positioned to be the first formal adopter, followed by ANVISA. The realistic timeline for ANMAT formal Annex 2 acceptance is Q4 2026 to Q1 2027. ANVISA follows in H1 2027 to H2 2027.

    For sponsors making 2026 country sequencing decisions today, the implication is straightforward. Argentina is positioned as the natural lead LATAM jurisdiction for Annex 2-aligned protocols. Brazil follows. Mexico and Colombia continue to be evaluated case-by-case based on therapeutic-area depth and sponsor-specific requirements.

    The Bottom Line

    Latin America is no longer at the edge of global GCP. The June 3 Rio Assembly, the ANVISA hosting of the meeting, and the Step 4 advancement of E6(R3) Annex 2 together signal a structural shift that sponsors building modern trial designs should integrate into 2026-2027 strategy now rather than after the fact.

    The most expensive country sequencing decision is not the one made wrong. It is the one made too late, after the trial design has been frozen and the regulatory pathway is already constrained by choices that no longer reflect the current landscape.

    If you are evaluating an Annex 2-aligned FIH protocol for 2026 or 2027 and want a LATAM country sequencing analysis that integrates the new Rio Assembly outcomes, the team at bioaccess® can produce a tailored proposal within two weeks. We have run first-in-human and pivotal-stage trials across Argentina, Brazil, Colombia, Mexico, and Panama since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Brazil’s 90 Day Clinical Trial Review Cap: What Medtech Sponsors Should Do Before Submitting

    Brazil’s 90-Day Clinical Trial Review Cap: What MedTech Sponsors Should Do Before Submitting

    Brazil has moved from being a “high-potential but unpredictable” country for early-stage MedTech studies to a jurisdiction with a defined statutory review clock. For sponsors, that shift is not just a speed story — it is a planning story. When review timelines become shorter and more predictable, the relative impact of preventable sponsor-side errors gets larger.

    This article is written for MedTech founders, clinical operations leaders, and regulatory directors who want to run first-in-human (FIH) or early feasibility work in Brazil without losing weeks to rework. We focus on what you can control before submission: dossier readiness, ethics strategy, local operational prerequisites, and vendor orchestration.

    Why a faster regulatory clock changes the sponsor playbook

    Short timelines compress decision-making. If you used to “fix it after ANVISA feedback,” you may no longer have that luxury — because site contracts, import permits, radiology workflows, and ethics committee coordination can become the rate-limiting steps. A faster clock also forces clearer internal governance: who owns the final protocol, the risk assessment, the device technical file, and the country-specific annexes?

    Practically, the sponsor question becomes: How do we arrive at Day 0 with no missing pieces? The goal is to avoid pauses caused by translation gaps, document format mismatches, incomplete investigator packages, or unaligned device documentation.

    Pre-submission checklist: what to lock down before Day 0

    • Protocol version control: Confirm the final protocol, synopsis, schedule of assessments, and statistical plan are aligned — and that the same versions appear in every submission component.
    • Risk classification and device description: Ensure the device description, intended use, instructions for use, and risk analysis are consistent across documents. Inconsistency is one of the most common sources of questions.
    • Investigator and site packages: Collect CVs, training evidence, GCP documentation, and site capabilities early. In Brazil, the operational readiness of sites can become as important as the regulatory dossier.
    • Translations and local formatting: Build time for Portuguese localization and formatting checks. A strong translation is not only linguistic — it must preserve clinical meaning and match annex references.
    • Informed consent strategy: Prepare consent language that is clear, compliant, and aligned to local norms. If your device includes software, connectivity, or data transfer, incorporate that into consent and data handling text.
    • Import and logistics planning: Map the path for device shipment, labeling, and storage. Even for non-radioactive devices, customs, temperature needs, and distribution responsibilities can derail timelines.

    Parallel ethics + regulatory review: how to operationalize it

    When a system allows parallel tracks, the bottleneck often shifts to coordination. Sponsors should treat ethics submission as a project with its own critical path, not as an administrative afterthought. Build a unified submission calendar and align on:

    • Sequence of internal approvals: Decide who signs off on ethics content and who owns final responses.
    • Site-by-site variance: Even with a national framework, each site can introduce operational nuance. Standardize as much as possible, but plan for local adjustments.
    • Response management: Pre-write response templates for common questions (risk/benefit, recruitment strategy, device safety, data management) so you can move quickly.

    For FIH and early-stage work, ethics committees will often focus on patient protection and feasibility: training, emergency procedures, follow-up, and the practical ability of the site to manage adverse events. Your dossier should show readiness, not just compliance.

    What MedTech sponsors often underestimate in Brazil

    Speed-friendly frameworks do not eliminate complexity; they amplify the cost of under-planning. The most common underestimates include:

    • Data and privacy workflows: If your study uses digital endpoints or remote monitoring, align data flows, storage, and access controls early.
    • Device accountability: Plan how devices will be tracked, stored, returned, and reconciled. Accountability gaps create audit risk and can slow activation.
    • Training: Documented training is not optional in early-stage device studies. Build training into your timeline and capture evidence systematically.
    • Vendor interdependencies: CRO, imaging core lab, shipping/logistics, and local regulatory support must operate from the same timeline assumptions and document set.

    FAQ

    1) Does a statutory review cap guarantee approval in 90 days?
    No. A cap can improve predictability, but the practical timeline still depends on dossier quality, completeness, and how quickly questions are resolved.

    2) Should we treat Brazil as a first-choice country for FIH studies?
    Brazil can be compelling when the patient population, investigator expertise, and activation path fit the product. Sponsors should evaluate Brazil alongside other Latin American jurisdictions based on feasibility, ethics speed, and operational readiness.

    3) What’s the biggest sponsor-side mistake?
    Submitting with misaligned documents (protocol vs. device description vs. risk file) and assuming issues can be fixed “during review.” In faster systems, that approach often costs more time, not less.

    Bottom line: If your goal is to capture the benefit of a faster review framework, your work starts well before Day 0. A sponsor-side checklist — executed early — is often the difference between a fast approval and a slow cycle of preventable questions.

  • Law 14.874/2024 Explained: How Brazil’s 90‑Business‑Day Review Window Changes Early‑Stage Clinical Trial Planning

    Law 14.874/2024 Explained: How Brazil’s 90‑Business‑Day Review Window Changes Early‑Stage Clinical Trial Planning

    For MedTech and Biopharma teams considering Latin America, Brazil has historically been seen as a high-potential but hard-to-predict jurisdiction for early-stage clinical trials. That uncertainty can inflate budgets and push teams toward smaller, single-country feasibility strategies.

    Brazil’s Law No. 14.874/2024 introduced a clear constraint: for primary petitions for clinical trials with humans (for marketing authorization purposes), the health analysis may not exceed 90 business days. The law also describes how additional information requests affect the clock.

    This article explains what the 90-business-day window means in practical terms, how sponsors can build a sponsor-ready activation timeline around it, and what pitfalls still cause delays even in a more predictable regime.

    What the law changed (and what it did not)

    The most sponsor-relevant shift is that a defined review window reduces planning ambiguity. A predictable maximum review duration enables better parallelization: ethics preparation, site contracting, and supply chain setup can be scheduled against a more reliable regulatory milestone.

    However, a legal review window does not automatically eliminate operational delays. Sponsors still need to manage:

    • Dossier completeness and consistent technical documentation
    • Ethics sequencing across institutions and committees
    • Import readiness for investigational product shipments
    • Site activation capacity (training, contracting, scheduling)

    In other words, the “clock” helps the regulatory portion of the critical path—but the rest of the program still needs a plan.

    Translating “90 business days” into an activation timeline

    Sponsors often underestimate how different business days can be from calendar days when building a global timeline. A pragmatic approach is to create three layers:

    • Regulatory layer: submission, review window, and potential information request handling
    • Ethics layer: committee submissions and approvals (often overlapping but not identical to regulatory steps)
    • Operations layer: contracts, budget approvals, training, and supply chain readiness

    A sponsor-ready planning template for Brazil should include:

    • Week 0–2: lock document ownership, finalize submission-ready dossier, confirm translation requirements, and run an internal quality check.
    • Week 2–4: submit to the relevant bodies; initiate site contracting and budget cycles in parallel.
    • During review window: implement a weekly “readiness review” covering import documentation, device labeling alignment (if applicable), training scheduling, and monitoring plans.
    • Upon clearance + ethics alignment: initiate first shipment, conduct site initiation, and begin enrollment.

    The objective is to avoid a common failure mode: regulatory clearance arrives, but operations are not ready—so the team loses the predictability advantage that the defined window provides.

    How information requests can still create delays

    Even with a defined maximum window, sponsors should plan for information requests. The practical lesson is to assume that the first submission must be as complete as possible, and that the team must be ready to respond quickly.

    To reduce the chance of delays:

    • Assign a single submission owner responsible for consistency across protocol, investigator brochure (if applicable), device dossier, and administrative documents.
    • Create a rapid-response package before submission: technical specs, risk management summaries, labeling variants, and manufacturing documentation.
    • Pre-brief sites on likely follow-up questions so responses do not stall waiting for institutional input.

    Speed matters because information requests often pause progress until the sponsor responds, and slow responses can negate the benefits of the defined review period.

    Why Brazil’s predictability matters for LATAM multi-country strategy

    For some early-stage teams, Brazil may now be easier to include in a multi-country Latin America strategy when paired with other jurisdictions. The strategic value is not only speed—it is credibility of planning. When leadership teams can explain why the timeline is realistic, financing, vendor contracting, and site commitments become easier.

    To maximize the benefit, sponsors should treat Brazil as one component of a LATAM activation architecture:

    • Define a country sequencing strategy (which country starts first and why)
    • Standardize document templates across countries (with country annexes)
    • Build a supply chain plan that can support staggered activations without stockouts

    When done well, the result is not just a faster first patient in; it is a trial program that is easier to scale.

    FAQ

    Does the 90-business-day window guarantee approval?

    No. A defined window is about timing, not outcome. Sponsors still need a complete, well-justified dossier and an operational plan that supports ethics and site readiness.

    Should early-stage sponsors wait for Brazil before activating other LATAM countries?

    Not necessarily. Many sponsors can run activities in parallel across countries. The right choice depends on device complexity, supply chain constraints, and how quickly the sponsor can support multiple site activations.

    What is the single biggest mistake sponsors make with “faster” regulatory timelines?

    Assuming that regulatory speed automatically creates operational speed. The winning approach is to use predictability to parallelize work—contracts, training, and import readiness—so the program is ready when clearance arrives.

    Bottom line: Brazil’s Law 14.874/2024 gives sponsors a more predictable planning horizon. The teams that benefit most will be the ones that treat the regulatory window as a scheduling tool—and execute the operational readiness plan in parallel.

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.

  • First-In-Human In Brazil In 2026: A Practical Timeline For Sponsors

    First-in-Human in Brazil in 2026: A Practical Timeline for Sponsors

    Primary keyword: first-in-human trial Brazil timeline

    Brazil is increasingly on the shortlist for early-stage clinical development because sponsors can combine a large patient base with growing regulatory clarity. A recent policy analysis argued that Lei 14.874 de 2024 created the basis for a more predictable environment and, for the first time, establishes timelines and greater regulatory clarity for clinical studies.

    This article gives a practical, sponsor-side timeline for launching a first-in-human (FIH) study in Brazil in 2026—what to do first, what typically slows teams down, and how to sequence work so you do not lose weeks to preventable back-and-forth.

    1) Define the “Brazil-ready” FIH package (Weeks 0–2)

    Before any submission, align internal stakeholders on what “Brazil-ready” means. For most MedTech and biopharma sponsors, FIH readiness is not only a protocol question—it is also a documentation and site execution question.

    • Protocol and IB alignment: Ensure endpoints, safety monitoring, and dose-escalation logic are consistent with your global plan.
    • Country adaptations: Identify what must be localized or supplemented (consent language, site materials, labeling, and investigator documentation).
    • Feasibility assumptions: Confirm whether required imaging, lab, or procedural capabilities exist at target sites.

    Internal best practice: Create a single “FIH Brazil master checklist” with owners and due dates. Treat it as a deliverable, not an afterthought.

    2) Select sites for speed, not just prestige (Weeks 1–4)

    In FIH, startup speed is highly correlated with site readiness. Sponsors often choose sites based on reputation, then discover contracting and operational realities late.

    • Prioritize operational maturity: Look for sites with dedicated research staff, established ethics processes, and experience with sponsor audits.
    • Validate recruitment pathways: Treatment-naive populations can be an advantage, but referral networks still matter.
    • Assess import and handling constraints: If your study uses temperature-sensitive materials, confirm storage and chain-of-custody procedures early.

    3) Build a parallel workstream plan (Weeks 2–6)

    The most common timeline mistake is running tasks sequentially that can be executed in parallel. Even when formal review clocks improve, sequential execution can erase the benefit.

    To compress time, run these workstreams at the same time:

    • Regulatory dossier preparation (quality, safety documentation, and trial authorization package)
    • Ethics submission package (site-specific documents and consent)
    • Contracts and budgets (CTA, indemnities, payment schedules, and monitoring model)
    • Supply and logistics readiness (import planning, labeling, storage validation, and back-up scenarios)

    Even when legal reforms aim to improve predictability, sponsors still need coordinated execution across stakeholders to realize those gains.

    4) Anticipate “hidden” startup time: contracts, import, and training (Weeks 4–10)

    Even when review timelines are favorable, sponsors can lose time after approvals due to operational bottlenecks:

    • Contract negotiation cycles: Build buffer time for legal review, redlines, and institutional sign-off.
    • Import and release: If your investigational product or device must be imported, confirm lead times and documentation requirements early.
    • Site initiation and training: FIH trials require strict adherence to safety procedures; schedule training sessions while approvals are in progress.

    Practical tip: Maintain a “go-live readiness dashboard” that tracks contract status, shipment readiness, and training completion. This prevents surprises when the green light arrives.

    5) A sponsor-friendly 2026 FIH timeline (example)

    Every program is different, but a realistic planning template looks like this:

    • Weeks 0–2: Brazil-ready protocol package, checklist, and internal alignment
    • Weeks 1–4: Site selection, feasibility, and early budget/CTA drafts
    • Weeks 2–6: Parallel dossier + ethics package finalization
    • Weeks 4–10: Contracts, import planning, training, and vendor setup
    • Weeks 10–14: Final site activation steps and first-patient readiness

    If you are aiming for speed, measure time-to-ready as rigorously as you measure time-to-approval. In many FIH programs, the fastest sponsors are simply the ones that avoid rework.

    FAQ: First-in-human trial Brazil timeline

    • How long does it take to start a first-in-human trial in Brazil?
      Timelines vary by protocol complexity and site readiness, but sponsors should plan for parallel regulatory and ethics pathways, early document localization, and realistic contracting and import lead times.
    • What is the biggest cause of FIH delays in Brazil?
      In practice, delays often come from incomplete documentation, late site selection, and underestimated startup logistics (contracts, import permits, and investigational product readiness), not just the formal review clock.
    • Can Brazil FIH data support US or EU submissions?
      Yes, when the trial is designed to international GCP standards and endpoints align with your global regulatory strategy, Brazilian data can be part of a broader evidence package.

    Need help planning an FIH startup in Brazil or across Latin America? bioaccess® supports sponsors with country startup planning, site activation, and operational execution—without exposing confidential details publicly.

  • Regulatory Harmonization in Latin America: What ANVISA’s Regional Cooperation Signals for Multi‑Country MedTech Trials

    Regulatory Harmonization in Latin America: What ANVISA’s Regional Cooperation Signals for Multi‑Country MedTech Trials

    Latin America is not a single regulatory market, but the region is moving toward more structured cooperation, reliance, and convergence. For MedTech sponsors running multi-country clinical programs, these shifts matter because they can change how dossiers are prepared, how evidence is reused, and how activation risks are managed.

    In June 2026, ANVISA reported participating in a PAHO-organized Regional National Regulatory Reference Authorities (NRAr) meeting in Buenos Aires focused on strengthening regulatory systems and expanding international cooperation. ANVISA also described bilateral discussions with multiple agencies (including FDA, Cofepris, Anmat, and Invima) and highlighted signing a memorandum of understanding with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.

    These developments do not eliminate country-by-country requirements. However, they signal a direction of travel: more formal cross-border collaboration, more alignment on good regulatory practices, and potentially more predictability for sponsors who plan strategically.

    1) Why “harmonization” matters for MedTech trial execution (not just strategy)

    When teams hear “regulatory harmonization,” they often think of policy. Operationally, the real value comes from:

    • Reuse of core evidence packages across multiple authorities
    • Fewer contradictory requirements that force protocol redesign
    • More predictable review expectations when agencies align with shared standards
    • Reduced activation friction when documentation formats converge

    For early-stage MedTech sponsors, reducing friction is not a luxury. It can be the difference between hitting a funding milestone and needing a bridge round.

    2) What ANVISA’s recent cooperation activity suggests

    ANVISA’s public update indicates three practical signals for sponsors:

    • Regional capacity-building is a priority: the NRAr meeting agenda included mechanisms for convergence and innovation, plus updates to PAHO’s regional policy for strengthening regulatory systems.
    • Reliance is becoming more explicit: ANVISA described an agreement with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.
    • Global credibility is a strategic goal: ANVISA highlighted progress toward WHO Listed Authority (WLA) recognition, which can influence how other stakeholders view Brazilian regulatory decisions.

    None of this means that a sponsor can file once and be approved everywhere. But it does mean sponsors should expect more structured cooperation and should design their evidence and documentation to be “portable.”

    3) How to design a “portable dossier” for Latin America

    A portable dossier is not a one-size-fits-all PDF. It is a controlled set of core modules that can be adapted with minimal rework. Practical components include:

    • Master protocol with annex-ready country adaptations (contact details, lab references, safety reporting specifics)
    • Device description and risk analysis aligned to internationally recognized principles (clear intended use, hazards, mitigations)
    • Clinical evaluation narrative that ties early feasibility data to the next evidence step
    • Quality and traceability package that supports import, accountability, and post-trial device handling

    The goal is to reduce “translation churn”—not just language translation, but repeated rewriting driven by different templates.

    4) Planning multi-country activation under partial convergence

    Even with convergence, activation remains a network problem. Practical planning considerations include:

    • Choose an anchor country with predictable timelines and strong sites to generate early momentum.
    • Open a second wave in parallel where operational readiness is high and import pathways are clear.
    • Use timeline intelligence from authoritative resources: for example, NIH ClinRegs summarizes that Brazil’s Law No. 14.874 sets a 90-business-day deadline for ANVISA’s analysis of primary petitions for clinical trials, while Peru’s INS must complete review and approval of a clinical trial application within a maximum of 30 working days.

    These published timelines are not the entire story, but they are a useful starting point for scenario planning and stakeholder alignment.

    5) What to watch next (and how to stay ahead)

    Regulatory convergence tends to move in “bursts,” driven by new policies, pilot programs, and bilateral agreements. Sponsors can stay ahead by:

    • Monitoring regulator cooperation news from agencies and PAHO
    • Building evidence packages that align with shared standards so they remain reusable as convergence increases
    • Running pre-activation risk reviews that consider import, ethics, and site readiness in each target country

    The most successful teams treat regulatory strategy as an operational lever. Convergence is valuable, but only if you translate it into a concrete activation plan.

    FAQ: Regulatory harmonization and multi-country trials in Latin America

    Is Latin America becoming a single regulatory market for MedTech trials?

    No. Each country retains its own laws and authorities. However, cooperation and convergence efforts can reduce friction and improve predictability over time.

    What recent sign suggests increased cooperation?

    ANVISA publicly described participating in PAHO’s NRAr meeting in Buenos Aires and reported signing a memorandum of understanding with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.

    How should sponsors respond today?

    Design a portable dossier, plan activation as parallel workstreams, and sequence countries based on both published timelines and on-the-ground operational readiness.

    Bottom line: regulatory harmonization is not a shortcut, but it is a trend sponsors can operationalize. Teams that build portable evidence and plan multi-country activation around predictable processes will be best positioned as convergence accelerates.

  • Brazil’s 90‑Business‑Day ANVISA Clock: How to Plan First‑in‑Human Activation Without Bottlenecks

    Brazil’s 90‑Business‑Day ANVISA Clock: How to Plan First‑in‑Human Activation Without Bottlenecks

    Brazil has moved from “unpredictable timelines” to a more clock-driven model for key clinical trial petitions. According to the U.S. NIH ClinRegs Brazil overview, Law No. 14.874 requires ANVISA’s analysis of primary petitions for clinical trials (including Clinical Drug Development Dossiers, DDCMs) to be completed within 90 business days. This is a meaningful planning advantage for MedTech and Biopharma teams designing first‑in‑human (FIH) or other early-stage studies in Latin America.

    But a defined regulator timeline does not automatically translate into a fast first-patient-in. Activation can still stall due to ethics sequencing, site contracts, import permits, labeling, budgeting, and operational readiness. The sponsors who benefit most are the ones who orchestrate the entire activation system around the review clock—not just the regulatory submission.

    This article provides a practical playbook for using Brazil’s defined review window to reduce uncertainty without compromising compliance. It is written for MedTech founders, clinical operations leaders, and regulatory directors planning early clinical evidence generation in Latin America.

    1) What the “90‑business‑day clock” means (and what it doesn’t)

    In many countries, the biggest activation challenge is not the technical content of the dossier—it is uncertainty. When timelines drift, every downstream dependency becomes harder: site selection, device logistics, vendor contracting, and financing.

    Brazil’s framework has introduced a clearer expectation. ClinRegs summarizes that ANVISA’s analysis of primary petitions for clinical trials with human beings “must be completed within 90 business days” under Law No. 14.874, with related implementing details in Resolução RDC No. 945 (including how the 90 business days are counted for DDCM/DEEC petitions).

    Important nuance: a regulator timeline is one piece of a multi-track activation pathway. If the sponsor treats the ANVISA clock as the entire schedule, they can still lose weeks or months elsewhere.

    2) Build an activation timeline like a network, not a checklist

    Fast activation is usually the result of parallelization, not heroics. A useful way to plan is to treat each workstream as a node in a network:

    • Regulatory dossier readiness (DDCM/DEEC content, translations, country-specific annexes)
    • Ethics committee readiness (Brazil CEP/CONEP strategy, submissions, anticipated questions)
    • Site readiness (feasibility, equipment, training, contracts, budgets)
    • Import and logistics readiness (customs broker, labeling, packaging, temperature control, returns)
    • Data and safety operations (eCRF build, SAE workflows, vendor setup, monitoring plan)

    In early-stage MedTech programs, the “critical path” often shifts midstream. For example, the device may be available, but site contract negotiation drags. Or the site is ready, but import documentation is incomplete. A network view helps you see what must be done in parallel so that the 90-day review window is not wasted.

    3) A practical pre-submission readiness package (what to have done before day 0)

    To benefit from predictable review windows, sponsors should aim to begin ANVISA review with minimal “churn” during the clock. In practice, this means building a readiness package before the submission date. Common elements include:

    • Protocol that is operationally executable: endpoints, visit schedule, and device handling that local sites can implement.
    • Risk-driven monitoring and safety plan: proportional to first-in-human risk, with clearly defined escalation pathways.
    • Brazil-ready informed consent: culturally appropriate language; processes for re-consent if amendments occur.
    • Import map: who will act as importer-of-record, how devices will be labeled, and the evidence trail for traceability.
    • Site contracts and budgets in draft form: so legal review does not become the gating item after regulatory clearance.

    Internal experience across Latin America shows that when sponsors plan only the submission, they often discover the “real bottleneck” later. Conversely, when they package readiness early, they can compress time-to-site-initiation after regulatory clearance.

    4) Common activation bottlenecks in Brazil (and how to design around them)

    Even with a defined regulator timeline, teams can lose time in avoidable areas. Here are recurring bottlenecks and practical ways to design around them:

    • Ethics sequencing misunderstandings: plan early for CEP/CONEP pathways and expected document sets; align translations and investigator documents up front.
    • Device logistics not protocolized: define receipt, storage, accountability, and disposal processes inside the protocol and site manuals.
    • Training delays: schedule investigator meetings and device training as soon as sites are selected; do not wait for final approvals to build training assets.
    • Budget misalignment: ensure site budgets reflect local realities (procedures, imaging, follow-up) to reduce renegotiation cycles.

    Operationally, the fastest programs are those where regulatory and operations leaders co-own the activation timeline, instead of treating it as a handoff from “regulatory” to “clinops.”

    5) How to use Brazil’s timeline advantage in a multi-country Latin America strategy

    Brazil’s defined review window can be especially valuable when used as one “anchor country” in a broader Latin America evidence strategy. Sponsors often seek to generate credible early data quickly, then expand into additional markets.

    To do this effectively:

    1. Design the protocol for exportability: align endpoints and data standards with future regulatory and reimbursement conversations.
    2. Standardize your core dossier: build a master package that can be adapted for different authorities without reinventing content.
    3. Plan the expansion pathway early: identify which countries can open in parallel (based on timelines, import complexity, and site readiness).

    For example, NIH ClinRegs indicates Peru’s INS must complete review and approval of a clinical trial application within a maximum of 30 working days, which may influence sequencing decisions depending on site availability and import readiness. The right path depends on the sponsor’s risk tolerance, funding timeline, and clinical endpoints.

    FAQ: Brazil’s ANVISA clock and first‑in‑human planning

    How long does ANVISA have to review key clinical trial petitions in Brazil?

    NIH ClinRegs summarizes that, under Law No. 14.874, ANVISA’s analysis of primary petitions for clinical trials (including DDCMs) must be completed within 90 business days.

    Does a 90-business-day regulator timeline guarantee fast first-patient-in?

    No. Activation speed depends on the entire system: ethics reviews, site contracts, import logistics, training, and operational readiness. A defined review window reduces uncertainty, but sponsors still need parallel planning.

    What is the biggest mistake sponsors make when planning first‑in‑human studies in Brazil?

    Treating regulatory submission as the whole project. The most common failure mode is not “regulatory delay”—it is downstream operational bottlenecks that were not designed into the timeline.

    Bottom line: Brazil’s defined review timeline can be a real advantage for early-stage programs, but only if sponsors plan activation as a coordinated set of parallel workstreams. If you treat the 90-day clock as a project management tool—not just a legal detail—you can reduce uncertainty and protect your first-patient-in date.

  • Anvisa’s 2026–2027 International Convergence Agenda: What Medtech Sponsors Need To Plan For

    ANVISA’s 2026–2027 International Convergence Agenda: What MedTech Sponsors Need to Plan For

    Brazil’s medical device regulator, ANVISA, is in the middle of the most aggressive period of international regulatory convergence in its history. Between the mid-2024 Brazilian Clinical Research Law (Lei 14.874) becoming fully operative on January 1, 2025, and the agency’s published 2026–2027 priorities, the rules around clinical trial submissions, post-market surveillance, software as a medical device (SaMD), and unique device identification (UDI) are all changing simultaneously.

    For MedTech sponsors planning to use Brazilian clinical data in US, EU, or Brazilian regulatory submissions, the next 18 months are a strategic window. Here is what is changing, why it matters, and how to plan for it.

    What Is Actually Changing

    Three convergence streams are running in parallel.

    1. Stronger international cooperation on device review. ANVISA has expanded its participation in international regulatory work-sharing arrangements, including the Medical Device Single Audit Program (MDSAP) and increased reliance agreements with FDA, EMA, and Health Canada-equivalent regulators. The practical effect: a device that has cleared review in a recognized reference jurisdiction can move through Brazilian registration substantially faster than under the old country-by-country framework.

    2. New SIUD database and UDI implementation. ANVISA’s Sistema de Informação de Identificação Única de Dispositivos Médicos (SIUD) is being phased in across 2026, requiring UDI assignment, labeling, and database submission for medical devices entering the Brazilian market. The phase-in follows risk class — Class IV (highest risk) and IVDs first, then descending through Class III, II, and I over the multi-year timeline.

    3. Software-as-a-medical-device pathway clarification. ANVISA has published updated normative instructions for SaMD classification, including AI-enabled clinical decision support, aligning more closely with FDA and IMDRF frameworks. For digital health and AI MedTech sponsors, the Brazilian pathway is now substantially more predictable than it was 24 months ago.

    All three streams are happening on top of the already-operative parallel review framework under Lei 14.874, which lets sponsors submit to ANVISA and the institutional ethics review system simultaneously rather than sequentially.

    Why the Window Matters Now

    For sponsors planning a Brazilian arm of a clinical trial — or a market access registration — three strategic implications flow from the current convergence wave.

    Documentation prepared for FDA or EU MDR is increasingly leverageable in Brazil. The technical file structure, risk classification reasoning, and clinical evidence summary you build for an FDA 510(k), De Novo, or EU MDR conformity assessment now translates more directly into ANVISA’s expectations than at any prior moment. The historical penalty of duplicating documentation across regions is materially smaller in 2026 than it was in 2022.

    The window for “first to file under the new framework” is open. Regulatory teams that align Brazilian submissions with the new convergence framework now will move ahead of teams that wait for further clarification. Once a sponsor has navigated one device through the new SIUD or updated SaMD pathway, every subsequent submission moves faster.

    Post-market obligations are being modernized. The new SIUD database is not just a labeling exercise — it forms the backbone of a more sophisticated post-market surveillance regime. Sponsors who structure their data capture and adverse event tracking systems to align with the new SIUD inputs from day one save significant retrofit cost later.

    Practical Planning for the Next 12 to 18 Months

    Three actions are appropriate for any sponsor with Brazilian exposure or plans:

    • Audit your UDI strategy now. If your device class is in the early SIUD phase-in, allocate budget and labeling capacity in 2026. If your device is in a later phase, use the next 12 months to harmonize UDI assignment with the FDA UDI database and the EU EUDAMED framework so all three jurisdictions are covered with a single system.
    • Restructure your technical file with convergence in mind. The 2026 reality is that one well-organized technical file should serve FDA, EU MDR, and ANVISA submissions with mostly mechanical translation steps and only modest jurisdiction-specific addenda. If your team is still maintaining three parallel files, the next 12 months are the right window to consolidate.
    • Engage early on SaMD classification. If your device incorporates software, AI, or clinical decision support, ANVISA’s updated framework means that a pre-submission classification conversation now yields meaningfully more predictable answers than two years ago. Take advantage of that predictability before launching the trial.

    Frequently Asked Questions

    Does the new ANVISA convergence framework affect clinical trial submission timelines?
    Yes — primarily through Lei 14.874’s parallel review mechanism, which lets ANVISA and ethics committees review submissions simultaneously instead of sequentially. The practical effect is a several-week to several-month reduction in start-up timelines compared with the pre-2025 framework, depending on device complexity.

    If my device is FDA-cleared, will ANVISA accept the FDA submission as-is?
    Not as-is. ANVISA’s reliance and convergence framework reduces duplication but does not eliminate the need for a Brazil-specific submission. What it does change is that your FDA-aligned technical file, risk classification logic, and clinical evidence package now translate more directly into ANVISA expectations, with smaller jurisdiction-specific gaps to fill.

    How does the SIUD database affect sponsors who do not yet sell in Brazil?
    If you have no Brazilian commercial presence and no plans for one, SIUD does not directly apply. If you are running a clinical trial in Brazil intending to commercialize there later — or to use Brazilian data in support of a future commercial registration — building UDI alignment into your trial-stage device labeling now is materially cheaper than retrofitting it later.

    bioaccess® supports first-in-human and early-feasibility medical device trials across 10 Latin American countries, including Brazil under ANVISA’s modernized framework. Learn more at bioaccessla.com or book a strategy conversation at bioaccessla.com/book-a-meeting.

  • Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

    Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

    For MedTech founders and regulatory directors, “first patient in” is not a single milestone—it is the outcome of dozens of parallel workstreams that must converge at the right time. Brazil has become an increasingly attractive environment for early-stage studies because the country’s regulatory pathway has defined review timelines for parts of the process, including a 90-business-day window for ANVISA’s analysis of key clinical trial petitions as described by the U.S. NIH’s ClinRegs Brazil overview.

    But a fast clock on paper does not automatically translate into a fast activation in practice. Sponsors still lose weeks when ethics submissions, ANVISA dossiers, import readiness, and site enablement are treated as sequential tasks rather than an integrated program. This article provides a practical first-in-human (FIH) activation timeline for Brazil—designed for medical devices and combination products—so teams can predict the critical path, reduce avoidable rework, and protect study quality.

    Why Brazil is different for early-stage activation

    Brazil’s clinical research oversight operates as a dual system. On the regulatory side, ANVISA is responsible for clinical trial oversight, approvals, and inspections. On the ethics side, institutional Research Ethics Committees (CEPs) and the National Research Ethics Commission (CONEP) safeguard participant rights and may be required for certain studies, including some with foreign sponsorship. ClinRegs notes that clinical trials may only begin after both ethics and ANVISA approvals are in place, and that sponsors can submit in parallel rather than waiting for one decision before starting the other.

    For FIH programs, the key operational insight is that “parallel” only works if your team pre-builds the dossier and operational backbone in a way that prevents late-stage gaps. That means aligning protocol, investigator’s brochure (or device equivalent), risk management, investigational product logistics, and site readiness into one activation plan.

    A practical FIH activation timeline (week-by-week)

    The timeline below is a planning template. Your specific path will vary based on device risk class, whether the product is a device-only investigation or a drug-device combination, whether import is required, and whether CONEP review applies. Still, most FIH teams benefit from managing the activation plan as six overlapping phases.

    Phase 1 (Weeks 0–2): Activation blueprint and dossier alignment

    • Define the activation goal: first patient in, first-in-country, or first site activated—then translate it into a dated plan with owners.
    • Freeze core scientific documents: protocol, statistical approach (if applicable), investigator brochure/device technical file summary, informed consent draft, and safety monitoring plan.
    • Pre-brief sites: confirm investigator interest, feasibility, patient pool, and required imaging/lab capabilities.
    • Map the import path: determine whether investigational product import will be needed, what documents are required, and when to initiate customs planning.

    Common pitfall: teams treat feasibility as “business development,” then discover late that the site cannot execute key assessments. For FIH studies, feasibility should be treated as a protocol risk-control activity.

    Phase 2 (Weeks 2–4): Parallel submission readiness (ethics + ANVISA)

    ClinRegs indicates that clinical trial applications can be submitted in parallel in Brazil. Use that advantage. Your objective in this phase is not merely to “submit,” but to submit dossiers that survive the first pass without avoidable queries.

    • Ethics package readiness: ensure Portuguese-language materials, recruitment approach, participant protections, investigator CVs, and site documentation are complete.
    • Regulatory package readiness: align device description, risk analysis, prior testing, clinical rationale, and monitoring approach into an internally consistent narrative.
    • Operational readiness: contract templates, budget assumptions, data capture approach, and vendor onboarding plan.

    Tip: run an internal “approval simulation” meeting before submission. Ask: if the reviewer questions the risk–benefit logic, do we have a clear answer embedded in the dossier?

    Phase 3 (Weeks 4–10): Review window management and rapid-response loop

    ClinRegs describes a 90-business-day timeframe for ANVISA’s analysis of key clinical trial dossiers, with defined sponsor response windows when additional information is requested. Even with set timelines, the sponsor’s responsiveness and document discipline often determine whether the review stays on track.

    • Stand up a “question-response” war room: pre-assign technical owners (clinical, quality, regulatory, biostatistics, logistics) so questions can be addressed within days, not weeks.
    • Maintain a single source of truth: track every submitted document version and every response in a controlled repository.
    • Keep sites warm: train coordinators, initiate essential vendor qualification, and prepare for SIV scheduling so you can start immediately after approvals.

    Common pitfall: teams wait for approval before planning site initiation, then lose 2–4 weeks to avoidable scheduling and vendor delays.

    Phase 4 (Weeks 8–12): Import and investigational product readiness

    FIH programs fail more often from logistics than from science. If you need to import devices, kits, or ancillary supplies, design the import process as a parallel track, not an afterthought.

    • Confirm labeling and packaging requirements: ensure your investigational labeling supports clinical-use workflows and aligns with the protocol.
    • Build a customs-ready document pack: commercial invoice equivalents, certificates, and product descriptions that minimize ambiguity.
    • Create a buffer strategy: hold contingency inventory or stage supplies locally when feasible.

    Tip: for FIH devices, plan at least one “mock shipment” exercise or logistics rehearsal, even if it’s document-only. The point is to find gaps while time remains.

    Phase 5 (Weeks 10–14): Site initiation and first patient in

    • Run targeted SIVs: prioritize protocol-critical procedures, safety reporting, and data integrity steps.
    • Operationalize screening: define screening triggers, referral pathways, and investigator decision trees.
    • Monitor early execution: the first 1–3 patients usually reveal whether your trial design is workable in the real world.

    Common pitfall: launching without clear screening criteria and without real-time visibility into early deviations. For FIH, early deviations often signal that the trial design needs operational adjustments.

    Phase 6 (Weeks 14+): Stabilize, scale sites, and protect data quality

    • Scale site network deliberately: expand only after the first site demonstrates protocol adherence and predictable enrollment.
    • Harden the safety loop: ensure rapid reporting, investigator training, and sponsor review cadence.
    • Maintain audit readiness: document control and deviation management are not optional; they are how you preserve the value of your data for future submissions.

    Checklist: What to pre-build before you submit

    • Protocol + operational workflow map (how each visit is executed at the site)
    • Device/technology summary that is consistent across regulatory, ethics, and site materials
    • Risk management narrative that ties hazards to mitigations and monitoring
    • Import-readiness pack with clear product descriptors and shipping plan
    • Vendor onboarding plan (labs, imaging, data capture, logistics) aligned to activation dates
    • Response war room with named owners and draft response templates

    FAQ

    1) Can we submit to ethics and ANVISA at the same time in Brazil?

    Yes. ClinRegs indicates that clinical trial applications can be submitted in parallel, but trials should not start until both approvals are in place. The operational value is in reducing idle time by building parallel readiness workstreams.

    2) What typically delays first-in-human activation the most?

    In many FIH programs, delays come from late dossier inconsistencies, slow responses to reviewer questions, and underestimated import and site-startup tasks. Treat activation as a program with a critical path rather than a compliance checklist.

    3) How do we protect data quality while moving fast?

    Move fast by reducing rework—not by cutting corners. Standardize document control, train sites on protocol-critical steps, and implement real-time deviation monitoring so you can correct execution issues early.

    Educational content only. Sponsors should consult qualified regulatory and clinical research professionals for study-specific planning.

  • Brazil’s 90‑Day ANVISA Clock for First‑in‑Human MedTech Studies: A Sponsor-Ready Timeline

    Brazil’s 90‑Day ANVISA Clock for First‑in‑Human MedTech Studies: A Sponsor-Ready Timeline

    For MedTech founders and regulatory leaders, the difference between a credible first‑in‑human (FIH) plan and an expensive science project often comes down to one question: when will we be cleared to start? In Latin America, Brazil is increasingly attractive because the regulatory environment is becoming more predictable for sponsors who prepare correctly. The biggest practical shift is that Brazil’s current framework is designed around a defined review window for ANVISA’s assessment of primary clinical‑trial petitions.

    This article translates that “clock” into a sponsor-ready activation timeline—what to do first, what can run in parallel, and where teams still lose weeks. It is written for early-stage device companies planning a first-in-human or very early feasibility study and aiming to use Brazil’s speed without compromising compliance.

    1) What the “ANVISA clock” changes (and what it does not)

    A defined review window is only valuable if your submission is complete and internally consistent. In practice, teams still face delays from avoidable dossier defects, mismatched translations, missing proof of manufacturer authorization, or unclear risk management documentation.

    • What changes: Sponsors can build a tighter critical path because the regulatory review is no longer an open-ended variable.
    • What does not change: Poor dossier quality, unclear clinical rationale, and weak local operational readiness can still extend the activation timeline.

    Think of the “90-day clock” as a predictability multiplier. It rewards teams that treat activation as a program, not a document handoff.

    2) A sponsor-ready activation timeline for FIH MedTech studies in Brazil

    Below is a practical timeline for a single-country Brazil activation that is common for early-stage MedTech programs. Actual sequencing depends on device risk classification, study design, and whether you already have an audited quality system and finalized manufacturing documentation.

    Phase A (Weeks 0–2): Define your regulatory “story” and activation plan

    Before drafting anything, align internal stakeholders on four elements:

    • Clinical intent: What data must your FIH generate (safety, usability, performance, feasibility) to unlock your next milestone?
    • Risk position: A simple, defensible summary of hazards, mitigations, and residual risk.
    • Operational model: Which hospitals, investigators, and vendor partners can execute within your required timeline?
    • Regulatory endpoints: Which approvals are required (ethics, ANVISA, contracts, importation readiness) and what is the critical path?

    Common failure mode: Teams finalize the protocol without deciding how the device will be imported, stored, serviced, and returned—creating late-stage amendments and logistics rework.

    Phase B (Weeks 2–6): Build the dossier as an integrated package

    FIH dossiers fail not because the science is wrong, but because the package is incoherent. Aim to produce a “single narrative” across these documents:

    • Protocol + investigator materials: Clear objectives, endpoints, and monitoring plan.
    • Device technical file excerpts: What the device is, how it works, and how it is controlled.
    • Risk management + usability: Evidence that use-related risks are addressed in training, labeling, and design controls.
    • Manufacturing and quality evidence: Enough to support safety and traceability expectations.
    • Clinical rationale: Why FIH is appropriate now and why Brazil’s sites can execute safely.

    Best practice: Maintain a “regulatory crosswalk” table mapping each claim in the protocol (device description, intended use, risk controls) to supporting evidence in the technical file. This prevents contradictions that trigger regulator questions.

    Phase C (Weeks 4–8): Ethics readiness and site operational lock

    While the dossier is being finalized, lock down the operational prerequisites that routinely delay activation:

    • Site feasibility confirmation: Not generic interest—confirmed equipment compatibility, OR slots, and patient flow.
    • Contracts and budget: Early alignment with hospital administration avoids last-minute legal stalls.
    • Training plan: How will you prove investigator training and competency for first uses?
    • Device logistics: Importation responsibilities, packaging validation, and field support processes.

    FIH timelines improve when ethics, contracts, and logistics are treated as first-class workstreams—not “post-approval tasks.”

    Phase D (Weeks 8–20): Regulatory review window and question management

    Once submitted, your main objective is to minimize cycles. Even with a defined review window, questions can reset practical timelines. Sponsors can reduce rework by planning for:

    • Rapid response capability: A named owner who can coordinate answers across engineering, QA/RA, and clinical.
    • Document control discipline: Consistent versioning, translation control, and traceability of edits.
    • Pre-drafted evidence packets: Sterilization summary, labeling package, risk management summary, device master record excerpts.

    Tip: When responding to questions, avoid “new storylines.” Keep answers anchored to the original intended use and risk position unless a formal amendment is required.

    3) Where FIH teams still lose time in Brazil

    Even with improved predictability, sponsors still lose weeks in three recurring areas:

    • Under-scoped translations: Technical and clinical translations require domain expertise, not generic language services.
    • Unclear importer/registration model: If responsibilities for importation and regulatory representation are not defined, device availability becomes the bottleneck.
    • Late site readiness: Contracts, budgets, and first-case scheduling often lag behind the regulatory path.

    The fix is not “work faster.” The fix is to design an activation system where regulatory, quality, and operations are integrated from day one.

    4) A practical checklist before you start your FIH activation

    • Have we defined the minimum FIH dataset required for our next financing or partnership step?
    • Is our intended use and risk position consistent across protocol, device description, and labeling?
    • Do we have a locked plan for importation, storage, servicing, and returns?
    • Are our sites contract-ready with budgets aligned and first-case logistics mapped?
    • Do we have a “rapid response” team prepared for regulator questions?

    FAQ: Brazil first‑in‑human MedTech study activation

    1) Can a defined review window guarantee my exact start date?

    No. It improves predictability, but start dates still depend on dossier quality, question cycles, ethics timing, contracts, and logistics.

    2) What is the most common avoidable delay for early-stage sponsors?

    Incoherent documentation—contradictions between protocol claims and device evidence, plus weak translation and version control.

    3) Should we activate Brazil as a stand-alone FIH or part of a multi-country plan?

    Many MedTech startups start with a focused single-country activation to generate clean early human data quickly, then expand once operational learning is captured.

    Conclusion: Brazil’s evolving framework can give FIH sponsors a more predictable regulatory path—but only if you build a dossier and activation plan that is operationally executable. Treat the “ANVISA clock” as a program milestone, not a date, and you can turn regulatory predictability into faster, safer first-in-human learning.